Lily Yang, MD, PhD is a professor of surgery and radiology and a prominent researcher. Dr. Yang's research experiences include tumor immunology, cancer stem cells, cancer gene therapy, apoptosis resistance, molecular targeted cancer therapy, nanoparticle imaging probes and theranostic nanoparticles for targeted cancer therapy and imaging.
Dr. Yang is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. She is a chartered member in the Study Section of the Development of Therapeutics at NIH.
Education
Dr. Yang received her medical training in China at West China University of Medical Sciences and at the Chinese Academy of Preventive Medicine. She received her PhD in molecular and cellular biology at Brown University. She had postdoctoral trainings in the Gene Therapy Laboratories at University of Southern California and in the Department of Genetics and Molecular Medicine Center at Emory University.
Titles & Roles
Professor, Surgery, and Radiology and Imaging Sciences
Emory University School of Medicine
Nancy Panoz Chair of Surgery in Cancer Research
Emory University School of Medicine
Director, Surgical Oncology Nanomedicine Research Lab
Emory University School of Medicine
Professional Memberships
Dr. Yang holds professional memberships with the American Association for Cancer Research, American Society of Nanomedicine and National Cancer Institute Alliance for Nanotechnology in Cancer.
Research
Dr. Yang's research projects focus on the development of novel cancer nanotechnologies and imaging methods to address the major challenges in clinical oncology of early cancer detection, targeted drug delivery, overcoming drug resistance, assessment of therapeutic response using non-invasive imaging, and image-guided surgery.
Recently, Dr. Yang and Huabei Jiang, PhD, of the University of Florida, received a multiple PI R01 grant from the National Institute of Biomedical Imaging and Bioengineering of the NIH. The grant will fund a four-year project to develop and test a multimodal imaging system and targeted nanoprobes for image-guided treatment of breast cancer. The study is a response to chemotherapy being largely ineffective for over 60% of patients with triple negative breast cancer.
Dr. Yang is a member of the editorial boards of a variety of scientific journals, such as Apoptosis, Nanomedicine: Nanotechnology, Biology and Medicine, Theranostics, Breast Cancer-Targets and Therapy, American Journal of Nuclear Medicine, and Molecular Imaging. She has served as a scientist reviewer for multiple NIH study sections, the Breast Cancer Research Program of the Department of Defense, the National Science Foundation, and the California Breast Cancer Research Program as well as many other national and international funding agents.
